Tuberculosis News and Research RSS Feed - Tuberculosis News and Research

Tuberculosis (TB) is a bacterial infection caused by a germ called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but they can also damage other parts of the body. TB spreads through the air when a person with TB of the lungs or throat coughs, sneezes or talks. If you think you have been exposed, you should go to your doctor for tests as soon as possible. You are more likely to get TB if you have a weak immune system.
Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year. [More]
Study finds increasing size of elderly population as major contributor to TB infection in China

Study finds increasing size of elderly population as major contributor to TB infection in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid, FIND announce receipt of CE-IVD status for Xpert HIV-1 Qual test

Cepheid and FIND today announced that Xpert HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. [More]
Autophagy: A new approach to fighting tuberculosis

Autophagy: A new approach to fighting tuberculosis

A new approach to combatting tuberculosis would take advantage of a complex, natural process called autophagy that the human body uses to recycle nutrients, remove damaged cell components, eliminate invading bacteria, and respond to inflammation. [More]
Infectious diseases experts release new guidance to avoid infections during hospital visits

Infectious diseases experts release new guidance to avoid infections during hospital visits

Leading infectious diseases experts have released new guidance for healthcare facilities looking to establish precautions for visitors of patients with infectious diseases. The guidance looks to reduce the potential for healthcare visitors in spreading dangerous bacteria within the healthcare facility and community. [More]
Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences launches skin test that helps physicians manage Valley Fever infections

Nielsen BioSciences announced today the launch of SPHERUSOL (Coccidioides immitis Spherule-Derived Skin Test Antigen), a skin test that provides valuable data to physicians managing Valley Fever infections. SPHERUSOL has been approved by the U.S. Food and Drug Administration as the only skin test to detect an immune response to the fungus called Coccidioides, or "cocci," in patients with history of the disease. [More]
Case Western Reserve researchers explore ways to treat, cure TB

Case Western Reserve researchers explore ways to treat, cure TB

After discovering a unique group of people resistant to tuberculosis (TB) infection, Case Western Reserve researchers are leading an international team dedicated to understanding exactly how they fight off a disease that claims 1.5 million lives each year. [More]
New resource available to help older Chinese Americans better understand their healthcare needs

New resource available to help older Chinese Americans better understand their healthcare needs

On the eve of National Minority Health Month, which helps raise awareness for disparities in health and care among minorities in the U.S., a new resource is available to help one such group, older Chinese Americans, better understand and drive their own well-being. [More]
Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate immune cells to fight against bacterial infections, Emory researchers have found. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality. [More]
Mayo Clinic Center for Tuberculosis introduces new medical journal

Mayo Clinic Center for Tuberculosis introduces new medical journal

The Mayo Clinic Center for Tuberculosis, a regional training and consultation center at Mayo Clinic's campus in Rochester, Minn, is today launching a new medical journal, the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. [More]
TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

TB Alliance receives Australian DFAT grant to support late-stage clinical trials of new TB drugs

TB Alliance, a not-for-profit product development partnership with the mission of developing better, faster, and affordable drugs for tuberculosis (TB), has received a grant from the Australian Department of Foreign Affairs and Trade to support late-stage clinical trials of new TB treatments. [More]
The fight continues to end tuberculosis

The fight continues to end tuberculosis

Today is World TB Day. The Centenary Institute is one of the leading medical research institutes in Australia championing the fight to put an end to this insidious disease. [More]
Researchers use genetic information to track the fatal spread of multidrug-resistant TB

Researchers use genetic information to track the fatal spread of multidrug-resistant TB

Scientists have for the first time used DNA sequencing to trace the fatal spread of multidrug-resistant tuberculosis between patients in the UK. [More]
Scientists use DNA sequencing to trace the spread of drug-resistant TB

Scientists use DNA sequencing to trace the spread of drug-resistant TB

Scientists have for the first time used DNA sequencing to trace the fatal spread of multidrug-resistant tuberculosis between patients in the UK. [More]
EMA approves Baylor's hollow fiber system for development of TB drugs

EMA approves Baylor's hollow fiber system for development of TB drugs

The European Medicines Agency (EMA), the equivalent of the U.S. Food and Drug Administration, has approved the use of the hollow fiber system for the development of drugs to treat and prevent tuberculosis (TB). [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
Advertisement